Status:

RECRUITING

Circulating Tumour Cells Characterization in Breast Cancer Patients

Lead Sponsor:

Istituti Clinici Scientifici Maugeri SpA

Collaborating Sponsors:

Carlo Morasso

Conditions:

Breast Cancer

Eligibility:

FEMALE

18-90 years

Brief Summary

In the current scenario, a reliable liquid biopsy method for predicting outcomes in solid tumors, especially among breast cancer patients, is lacking. Circulating Tumor Cells (CTCs) serve as crucial i...

Detailed Description

This is an experimental, prospective and monocentric study. This study involves consecutive patients with diagnosis of breast cancer (BC), including early breast cancer and metastatic breast cancer pa...

Eligibility Criteria

Inclusion

  • female patients with diagnosis of metastatic breast cancer, confirmed by clinical practice staging exams.
  • female patients with biopsy-confirmed diagnosis of early-breast cancer candidate for primary surgery after multidisciplinary evaluation.
  • patients not affected by any neoplastic disease.

Exclusion

  • Diagnosis of any neoplastic disease

Key Trial Info

Start Date :

December 1 2022

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 31 2025

Estimated Enrollment :

80 Patients enrolled

Trial Details

Trial ID

NCT06048835

Start Date

December 1 2022

End Date

December 31 2025

Last Update

November 25 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Istituti Clinici Scientifici Maugeri SpA

Pavia, Lombardy, Italy, 27100

Circulating Tumour Cells Characterization in Breast Cancer Patients | DecenTrialz